H ypertension is a leading cause of cardiovascular disease (CVD) and premature death in the United States and worldwide. [1] [2] [3] Observational epidemiology studies have shown a linear association between usual blood pressure (BP) levels and risk of CVD and all-cause mortality, with the lowest risk at a systolic BP (SBP) level of 115 mm Hg. 4 The Systolic Blood Pressure Intervention Trial documented that an intensive SBP treatment target of less than 120 mm Hg was associated with significant reductions of 25% for major CVD and 27% for all-cause mortality in individuals at high risk for CVD. [5] [6] [7] A 2017 meta-analysis of BP-lowering trials 8 also demonstrated significant and linear associations between mean achieved SBP and the risk of CVD and all-cause mortality, with the lowest risks in randomization groups with mean achieved SBP of 120 to 124 mm Hg. 8 Supported by evidence on intensive BP treatment, the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults recommended lower BP thresholds for initiation of antihypertensive medication and treatment goals than previous hypertension guidelines. [9] [10] [11] It is important to estimate the potential associations of these changes with treatment of hypertension and consequent CVD and mortality in the US population. Muntner et al 12 reported a hypertension prevalence of 45.6% and a percentage of US adults recommended for antihypertensive treatment of 36.2% in 2011 through 2014 under the new guideline. 12 The objectives of our analysis are 2-fold: to compare the estimated proportions of US adults in 2013 through 2016 defined as having hypertension or recommended for antihypertensive treatment per the 2017 and 2014 hypertension guidelines and to estimate the potential associations of treatment goals with risk reduction of major CVD and all-cause mortality and increases in adverse events in the US adult population.
Methods

Estimating Proportions of Hypertension and Eligibility for Antihypertensive Treatment
A more detailed description of the methods is available in the eMethods in the Supplement. The National Health and Nutrition Examination Survey (NHANES) uses a complex, stratified, multistage probability cluster sampling design to select representative samples of the US civilian, noninstitutionalized population. 13 Our analyses were limited to NHANES 2013 to 2016 participants 20 years and older (n = 11 062). Further exclusions were made for those who did not have 3 BP measurements (n = 565), had missing data on antihypertensive treatment (n = 10), and had missing data needed to define diabetes, chronic kidney disease (CKD), 10-year predicted risk of CVD, or history of CVD (n = 741). After exclusions, 9746 were used for this analysis. This study was approved by the Tulane University institutional review board, and all participants provided written informed consent as part of the individual protocols of the included studies.
In NHANES, 3 BP measurements were taken using a standard protocol, and the mean of them was used for analysis. Diabetes was defined as glycated hemoglobin level greater than 6.5% (to convert to proportion of total hemoglobin, multiply by 0.01), fasting serum glucose level of at least 126 mg/dL (to convert to millimoles per liter, multiply by 0.0555), nonfasting serum glucose level of at least 200 mg/dL, or selfreported history of diabetes and current use of glucoselowering medication.
14 Estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, 15 and CKD was defined as albumin-to-creatinine ratio of at least 30 mg/g or estimated glomerular filtration rate of 60 mL/min/1.73 m 2 or less. High CVD risk is defined as self-reported history of CVD (coronary heart disease, stroke, or heart failure) or 10-year predicted CVD risk of at least 10% using the ACC/AHA Pooled Cohort Equation.
9, 16 We assessed hypertension status and eligibility for pharmacologic treatment according to criteria from the 2014 evidence-based guideline and the 2017 ACC/AHA guideline ( Table 1) . 9, 10 All analyses used NHANES sampling weights to obtain US nationally representative estimates. These weights were recalibrated based on the proportion of participants missing data by age, sex, and race/ethnicity within each NHANES cycle. The numbers of CVD or deaths that could be reduced if the entire population achieved SBP treatment goals were computed using SBP distributions in the US population and the population attributable risks (PARs) related to SBP treatment goals.
Systolic BP Distributions
We estimated the proportion of US adults 40 years and older in each of 8 SBP categories (<130 mm Hg, 130-134 mm Hg, 135-139 mm Hg, 140-144 mm Hg, 145-149 mm Hg, 150-154 mm Hg, 155-159 mm Hg, and ≥160 mm Hg) by subgroups of sex, age, race/ethnicity, and hypertension guideline treatment categories. Data from NHANES 2011 to 2016 were combined to provide sufficient sample size for adults 40 years and older (n = 11 184). Those who did not have 3 BP measurements (n = 896), had missing data on antihypertensive treatment (n = 13), and had missing data needed to define diabetes, CKD, 10-year predicted risk of CVD, or history of CVD (n = 946) were excluded. After exclusions, 9329 participants were included in this analysis.
Incidence of Major CVD and All-Cause Mortality
We pooled individual-level data of 30 285 participants from 4 community-based US cohort studies: the Atherosclerosis Risk in Communities Study, 17 the Cardiovascular Health Study, 18 the Framingham Offspring Study, 19 and the Multi-Ethnic Study of Atherosclerosis. 20 We used Poisson regression models to estimate incidence of major CVD (coronary heart disease, stroke, heart failure, and CVD deaths) and all-cause mortality by age, sex, race/ethnicity, and hypertension guideline categories. The estimates were calibrated to reflect an annual 2.6 million major CVD events (795 000 stroke, 935 000 coronary heart disease, and 870 000 heart failure) 21 and 2 488 667 all-cause deaths 22 in the US population aged 40 years and older.
Hazard Ratio Estimation
We conducted a network analysis of 42 antihypertensive clinical trials to estimate hazard ratios for CVD and mortality comparing each of the 8 SBP categories. 8 Briefly, clinical trials that randomly allocated patients to an antihypertensive medication, control, or treatment target and reported a difference in mean achieved SBP of 5 mm Hg or more between comparison groups were included. Hazard ratios for each possible SBP comparison were calculated using Markov Chain Monte Carlo simulation. To account for trial heterogeneity in intervention duration and baseline risk of CVD or mortality, we adjusted for trial length and event rate (or mortality) in the reference groups for each trial in the model. 23 
Population Attributable Risks and Events Reduced
We calculated age-, sex-, and race/ethnicity-specific PARs of CVD and mortality owing to SBP higher than recommended treatment goals using the following formula:
where p i is the proportion of SBP category i, HR i is the hazard ratio of CVD (or deaths) in SBP category i, and k is the total number of SBP categories. A given PAR represents the proportion of CVD events (or deaths) that could be reduced by lowering the age-, sex-, and race/ethnicity-specific population's SBP level to treatment goals based on guideline treatment categories. We multiplied the age-, sex-, and race/ethnicity-specific PARs by the total number of annual CVD events (or deaths) in the US population 40 years and older to estimate the absolute reduction in number of events (or deaths). In addition, we estimated CVD event (or death) reductions assuming 25%, 50%, and 75% of individuals achieved guideline-specific SBP targets in a sensitivity analysis.
Uncertainty Estimation
We accounted for uncertainty in the estimation of the proportion of SBP categories, annual event rates, and hazard ratios of BP treatment effects using Monte Carlo simulations. 24 For each age-specific, sex-specific, race/ethnicity-specific, and guideline category-specific calculation for each study outcome, 10 000 simulations were conducted. The 2.5th and 97.5th percentiles were used to form 95% confidence intervals. c High cardiovascular risk is defined as a history of cardiovascular disease (coronary heart disease, stroke or heart failure) or 10-year predicted cardiovascular disease risk of at least 10% using the pooled cohort risk equations.
Assessing Adverse Events
We systematically searched published clinical trials targeting SBP less than 130 mm Hg using MEDLINE and EMBASE. 8 Data on adverse events were extracted from each study independently and in duplicate by at least 2 investigators. Absolute risk differences between intervention and control groups on adverse events were combined using inverse variance weighting. Risk differences were applied to the number of individuals recommended to lower SBP levels to less than 130 mm Hg per the 2017 guideline to estimate the expected number of adverse events. Analyses were conducted using SAS, version 9.4 (SAS Institute, Inc) and R, version 3.4.2 (The R Foundation). A 2-sided P value less than 0.05 was considered statistically significant.
Results
Hypertension Prevalence
According to the 2017 ACC/AHA Hypertension Guideline, 45.4% of US adults (105.3 million) 20 years and older had hypertension, which was significantly higher than estimates per the 2014 hypertension guideline of 32.0% (74.1 million) ( Table 2) . The difference in reclassified hypertension was 13.5% or 31.3 million between the 2 guidelines. The difference was greatest in men and those aged 40 to 59 years.
Recommendation for Antihypertensive Treatment
According to the 2017 ACC/AHA hypertension guideline, 35.9% of US adults (83.2 million) were estimated to be eligible for antihypertensive treatment, which was significantly higher than the 31.1% (72.2 million) according to the 2014 hypertension guideline ( Compared with the 2014 guideline, the 2017 guideline is estimated to recommend slightly more men than women for antihypertensive treatment: 5.4% (6.0 million) increase in men and 4.1% (5.0 million) increase in women; and substantially more individuals 60 years and older (10.5% increase or 6.6 million) than those younger than 60 years (2.6% increase or 4.4 million). Increases in the proportions recommended treatment were similar by race/ethnicity groups. Among guideline categories, the 2017 guideline recommended more individuals 60 years and older without diabetes or CKD (13.4% or 4.7 million increases) and those with high CVD risk, diabetes, CKD, or 65 years and older (14.2% or 9.7 million increases) for antihypertensive treatment (Table 3) .
Risk Reduction of Major CVD and All-Cause Mortality
Systolic BP distributions by 2014 and 2017 guideline categories and age, sex, and race/ethnicity among US adults 40 years and older are shown in eTables 1 and 2 in the Supplement, while estimated event rates of CVD and all-cause mortality are shown in eTable 3 in the Supplement. Hazard ratios of CVD and allcause mortality associated with SBP levels of at least 130 mm Hg, at least 140 mm Hg, and at least 150 mm Hg from the network analysis are presented in eTable 4 in the Supplement.
An estimated 610 000 CVD events and 334 000 total deaths will be reduced annually in US adults 40 years and older if all individuals with hypertension achieve the 2017 hypertension guideline SBP treatment goals ( Table 4) . The corresponding reductions of CVD and all-cause mortality after achieving the 2014 hypertension guideline SBP treatment goals were 270 000 and 177 000, respectively. Therefore, implementation of the 2017 guideline could potentially further reduce 340 000 CVD events and 156 000 total deaths annually. Estimated risk reductions were observed in all subgroups of sex, age, and race/ethnicity. However, the magnitude of estimated risk reductions associated with implementing the 2017 guideline compared with the 2014 guideline were greater among those 60 years and older and individuals with high CVD risk, diabetes, or CKD (Table 4 ; eTables 5 and 6 in the Supplement). Additionally, the 2017 guideline resulted in a greater risk reduction than the 2014 guideline even when a comparatively lower percentage of patients with hypertension achieve 2017 guideline target BP levels (eTable 7 in the Supplement). For example, 50% achievement of the 2017 hypertension guideline would reduce an estimated 305 000 CVD events and 167 000 total deaths. On the other hand, 75% achievement of the 2014 hypertension guideline would reduce only 203 000 CVD events and 133 000 total deaths. The number needed to treat (NNT) to prevent 1 major CVD event was 70 (range, 63-91) in sex, age, and race/ethnicity subgroups according to the 2017 guideline; the NNT was 88 (range, 61-226) according to the 2014 guideline ( Table 4 ). The NNT for CVD was significantly lower in women and those younger than 60 years according to the 2017 guideline compared with the 2014 guideline. The NNT to prevent 1 death was 129 (range, 105-240) in sex, age, and race/ethnicity subgroups according to the 2017 guideline and 134 (range, 90-390) according to the 2014 guideline. The NNT for death was significantly lower among those younger than 60 years according to the 2017 guideline compared with the 2014 guideline.
Adverse Events
Three trials achieving SBP levels less than 130 mm Hg in the intensive treatment group and reporting adverse events were included in this analysis.
5,25-27 Treated SBP levels less than 130 mm Hg were significantly associated with increased risk of hypotension, syncope, electrolyte abnormality, and acute kidney injury or acute renal failure ( Table 5) . Implementing a SBP goal of less than 130 mm Hg according to the 2017 ACC/AHA guideline was estimated to increase 62 000 hypotension, 32 000 syncope, 31 000 electrolyte abnormality, and 79 000 acute kidney injury or acute renal failure events.
Discussion
The 2017 ACC/AHA hypertension guideline differs substantially from the 2014 evidence-based guideline, particularly re- Abbreviation: ACC/AHA, American College of Cardiology/American Heart Association. The new criteria increase the number of adults who would be newly diagnosed as hypertensive and receive lifestyle interventions and antihypertensive medication treatment. However, the new criteria also result in an increased number of adults diagnosed as hypertensive who might not be expected to develop CVD events. The health and economic consequences of the new diagnostic criteria for hypertension should be evaluated in future studies. We estimated that with the 2017 ACC/AHA hypertension guideline, 83.2 million US adults (35.9%) would be eligible for antihypertensive pharmacologic treatment. Of them, 27.9 million individuals (12.1%) would require initiation of antihypertensive medications and 29.9 million (12.9%) would require antihypertensive treatment intensification. Compared with the 2014 evidence-based hypertension guideline, an additional 11.0 million US adults (4.7%) were eligible for antihypertensive treatment according to the 2017 ACC/AHA hypertension guideline. The guideline further differentiates recommendations among those with stage 1 hypertension, based on 10-year CVD risk. While comprehensive lifestyle interventions based on 6 major components are recommended among all individuals with hypertension, they are the primary mode of intervention in those with 10-year CVD risk less than 10%. 9 The new treatment recommendations have the largest effect in individuals 60 years and older and those with high CVD risk, diabetes, or CKD. Lowering BP treatment goals from less than 150/90 mm Hg to less than 130/80 in adults with hypertension 60 years and older would result in a net increase of 6.6 million US adults (10.5%) requiring initiation of antihypertensive treatment and 9.9 million (15.5%) requiring treatment intensification. Likewise, lowering BP treatment goals from less than 140/90 mm Hg to less than 130/80 mm Hg in individuals with high CVD risk, diabetes, CKD, or 65 years and older would result in an increase of 9.7 million adults (14.2%) requiring initiation of antihypertensive treatment and 8.4 million (12.3%) requiring treatment intensification.
Research Original Investigation
We estimated that 610 000 major CVD events and 334 000 total deaths could be prevented annually in the United States if all individuals 40 years and older achieved the 2017 ACC/ AHA hypertension guideline SBP treatment goals. Compared with the 2014 guideline, the 2017 treatment recommendations could reduce an additional 340 000 major CVD events and 156 000 deaths annually among the US adult population aged 40 years and older. Furthermore, we estimated that the reductions of CVD events and total deaths were greater under the 2017 hypertension guideline even when fewer patients achieve the BP treatment target compared with the 2014 hypertension guideline. Additionally, the new treatment recommendations slightly improve NNT, 28 especially in individuals younger than 60 years, supporting a 2017 analysis suggesting intensive BP control is cost-effective, despite projected increases in office visits and medication use. 29 It has been well documented in clinical trials that BP lowering provided progressively greater absolute risk reductions as baseline risk increased. 30 Among individuals with heterogeneous CVD risk, such as those younger than 60 years, use of predicted baseline CVD risk to inform antihypertensive treatment decisions is evidence-based. We also estimated the likely adverse events of full implementation of the 2017 ACC/AHA hypertension guideline. Achieving SBP treatment goals of less than 130 mm Hg in patients with hypertension might increase risk of hypotension, syncope, electrolyte abnormality, and acute kidney injury or acute renal failure, although these events were uncommon. Furthermore, the numbers needed to harm for adverse events are substantially larger than the NNT for CVD and all-cause mortality risk reduction, suggesting the benefits of the lower SBP goal outweigh the potential risks. Based on potential risks associated with intensive BP lowering, the 2017 ACC/AHA hypertension guideline emphasizes individualized care, especially for elderly patients, using clinical judgment and pa- 12 These estimates are similar to our analyses, which used more recent NHANES 2013-2016 data. Furthermore, we estimated the absolute risk reductions of major CVD and all-cause mortality and the potential number of adverse events associated with implementation of the 2017 hypertension guideline. Therefore, our article provides a unique and important contribution to the discussion about the new hypertension guideline and antihypertensive treatment in the US population.
Limitations
Our study has several limitations. First, we had insufficient sample size from NHANES and US cohort studies to reliably estimate the effect of the new guideline within subgroups. Second, 3 BP measurements were obtained at 1 NHANES visit, while guidelines recommend BP measurements be taken at 2 separate clinical visits. The 2017 ACC/AHA guideline in particular promotes standardization and consistency of BP measurement, which is crucial in accurately identifying and managing those with hypertension. Third, because there were no US national data on CVD incidence, we used 4 US populationbased cohort studies to estimate incidence by subgroups, and calibrated event counts to values from AHA/National Heart, Lung, and Blood Institute reports. 21 
Conclusions
The 2017 hypertension guideline defines a significant increase in the prevalence of hypertension by 31.3 million (13.5%), and the proportion of US adults recommended for antihypertensive treatment by 11.0 million (4.7%). If SBP treatment goals were achieved, the 2017 ACC/AHA hypertension guideline recommendations are estimated to reduce major CVD events by an additional 340 000 and total deaths by an additional 156 000 compared with the 2014 evidence-based hypertension guideline but may increase the number of adverse events. The 2017 American College of Cardiology/American Heart Association guideline for the prevention, detection, evaluation, and management of high blood pressure in adults markedly reset the diagnosis and treatment of hypertension. 1 These new directives have resulted in the identification of more individuals with hypertension, more requiring antihypertensive therapy, and more requiring intensification of antihypertensive therapy. Muntner et al 2 set the revised prevalence of hypertension at 45.6%, or 103 million US individuals, with treatment recommended for 81.9 million or 36.2% of US individuals. These new directives and population health estimates have been met with alternative guidelines and strong concerns regarding risks. However, the data brought forward by Bundy et al 3 addressing compelling population benefits provide a strong counter and incite an argument for robust implementation. The risks of antihypertensive therapy are notable but also contextual; most of those newly diagnosed as having hypertension should be exposed to low-risk effective lifestyle management. Medical therapy when indicated is associated with certain risks, and the echo of "do no harm" is particularly apropos. Bundy et al . High CVD risk is defined as either a self-reported history of CVD (coronary heart disease, myocardial infarction, stroke, or heart failure) or a 10-year predicted CVD risk ≥10% using the ACC/AHA Pooled Cohort Equation among those without a history of CVD. 4, 5 We assessed hypertension status and eligibility for pharmacologic treatment according to the criteria from the 2014 Evidence-based Guideline and the 2017 ACC/AHA Guideline (Table 1 in main paper). 4, 6 Individuals reporting a history of hypertension and use of antihypertensive medications were classified as hypertensive and eligible for treatment. All analyses used NHANES sampling weights to obtain US nationally representative estimates. These weights were recalibrated based on the proportion of participants missing data by age, sex, and race/ethnicity within each NHANES cycle, and nonresponse was assumed to be missing at random within subgroups. Recalibration was done by dividing the subgroup-specific sum of the weights for those missing and not missing data by the subgroup-specific sum of those with non-missing data only to calculate a stratum-specific correction factor. Then the weight for each participant in each stratum with non-missing data was multiplied by this correction factor. This resulted in the sum of the new weights for those with non-missing data equal to the sum of the original weights for those missing and not missing data within each stratum. 7 Proportions and absolute numbers of persons defined by the two guidelines as having hypertension were estimated overall and by subgroup of sex, age, and race/ethnicity. The proportion and absolute numbers of persons eligible to initiate pharmacologic treatment under the two guidelines was also calculated overall and by current treatment status and within subgroups of demographic characteristics and guideline treatment categories. Population characteristics of hypertensive individuals according to the two guidelines were also calculated and compared using 2 -tests for categorical and Ftests for continuous variables.
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Evaluating Predicted Risk Reductions of CVD and All-cause Mortality
The analyses included 4 components in the following sequence: (1) the proportion of systolic BP categories based on NHANES data was estimated; (2) the incidence rates of major CVD and all-cause mortality based on pooled cohort studies were estimated; (3) the hazard ratios of major CVD and all-cause mortality associated with systolic BP treatment goals were estimated from a meta-analysis of clinical trials; (4) the population-attributable risks (PAR) related to systolic BP treatment goals were calculated, and the numbers of CVD or deaths that could be reduced if the entire population achieved systolic BP treatment goals were computed by multiplying each outcome by the PAR for each age, sex, race/ethnicity, and hypertension guideline category. Details about each component of the sequence are detailed below.
Systolic BP Distributions
We estimated the proportion of US adults aged ≥40 years in each of eight systolic BP categories (<130, 130-134, 135-139, 140-144, 145-149, 150-154, 155-159, and ≥160 mmHg) by subgroups of sex, age, race/ethnicity, and hypertension guideline treatment categories. Data from NHANES 2011-2016 were combined to provide sufficient sample size for adults aged ≥40 years (n=11,184). Those who did not have three BP measurements (n=896), had missing data on antihypertensive treatment (n=13), and had missing values for variables needed to define diabetes, CKD, 10-year predicted risk of CVD, or history of CVD (n=946) were excluded. After exclusions, 9,329 participants were included in this analysis.
Incidence of Major CVD and All-cause Mortality
We pooled individual-level data of 30,285 participants from four community-based US cohort studies: the Atherosclerosis Risk in Communities (ARIC) Study, 8 the Cardiovascular Health Study (CHS), 9 the Framingham Offspring Study (FOS), 10 and the Multi-Ethnic Study of Atherosclerosis (MESA). 11 Detailed design and methods of these cohort studies have been published previously. [8] [9] [10] [11] For the present analysis, incident major CVD events comprised myocardial infarction (MI), fatal coronary heart disease (CHD), stroke, and congestive heart failure (CHF). CVD event and death ascertainment methods were similar among the four cohort studies. [8] [9] [10] [11] [12] [13] [14] The ARIC study is an ongoing population-based prospective study of 15,792 white and black participants aged 45-64 years recruited from four US communities during 1987-1989. The participants were reexamined every three years until 1996-1998 and follow-up from 2000 to 2011 for validated incident CVD events and deaths. 8 A total of 15,121 individuals were included in the datasets received from BioLINCC. Of these, 14,855 remained after excluding individuals with missing data needed to define diabetes, CKD, 10-year predicted risk of CVD, or history of CVD. Incident CVD events and deaths were adjudicated by the Morbidity and Mortality Classification Committee. 8 The CHS recruited 5,888 participants aged ≥65 years from four US communities during 1989-1993, and participants underwent annual extensive clinical examinations for a mean of 13 years. 9 A total of 5,888 individuals were included in the datasets from BioLINCC. Of these, 5,716 remained after excluding individuals with missing data needed to define diabetes, CKD, 10-year predicted risk of CVD, or history of CVD. Incident CVD events and deaths were adjudicated by the CHS Events Subcommittee. 12 The FOS recruited 5,124 offspring (and spouses) from the original Framingham Heart Study cohort during [1971] [1972] [1973] [1974] [1975] . 10 Participants were evaluated at roughly 4-year intervals following the baseline visit. We used examination 5 (1991-1995) as the baseline visit to limit missing data in defining diabetes, CKD, 10-year predicted risk of CVD, or history of CVD, resulting in an initial analysis sample size of 3,712 individuals included in the datasets received from BioLINCC. Of these, 2,955 remained after excluding individuals younger than 40 years and those with missing data needed to define diabetes, CKD, 10-year predicted risk of CVD, or history of CVD. Incident CVD events and deaths were adjudicated by a panel of three experienced investigators who evaluated medical records. 13 The MESA is a prospective cohort study of 6,814 persons aged 45-84 years without known CVD at baseline from six US communities. 11 Participants were recruited during 2000-2002 and measurement of subclinical CVD and risk factors were repeated over five examinations. A total of 6,814 individuals were included in the datasets received from BioLINCC. Of these, 6,759 remained after excluding individuals with missing data needed to define diabetes, CKD, 10-year predicted risk of CVD, or history of CVD. Incident CVD events and deaths were independently classified by two physicians who were members of the MESA mortality and morbidity review committee. 14 Cohort data are publicly available and were requested via the NIH Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). We used Poisson regression models to estimate incidence rates of major CVD (coronary heart disease, stroke, heart failure, and CVD deaths) and all-cause mortality by age, sex, race, and hypertension guideline categories. The estimates were calibrated to reflect an annual 2.6 million major CVD events (795,000 stroke, 935,000 CHD, and 870,000 heart failure) 15 and 2,488,667 all-cause deaths in the total US population aged 40 years and older. 16 Calibrated incidence rates per 1000 person-years are available in eTable 5.
Hazard Ratio Estimation
We conducted a network meta-analysis of 42 antihypertensive clinical trials to estimate hazard ratios for CVD and mortality comparing each of the eight systolic BP categories. 17 Briefly, clinical trials that randomly allocated patients to an antihypertensive medication, control, or treatment target and reported a difference in mean achieved systolic BP of 5 mmHg or more between comparison groups were included. Hazard ratios for each possible systolic BP comparison were calculated using Markov Chain Monte Carlo simulation. To account for trial heterogeneity in intervention duration and baseline risk of CVD or mortality, we adjusted for trial length and event rate (or mortality) in the reference groups for each trial in the model.
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Population Attributable Risks and Events Reduced
We calculated age-, sex-, and race/ethnicity-specific population attributable risks (PARs) of CVD and mortality due to higher than recommended systolic BP treatment goals using the following formula:
where p i is the proportion of systolic BP category i, HR i is the hazard ratio of CVD (mortality) comparing systolic BP category i to systolic BP category i-1, and k is the total number of systolic BP categories. For example, to calculate the PAR for a treatment target of <130 mm Hg, the product of the prevalence and hazard ratio (p i x [HR i -1]) for each successively higher SBP category (130-134, 135-139, 140-144, 145-149, 150-154, and ≥160 mmHg) are summed and then divided by this sum plus 1.
A given PAR represents the proportion of CVD events (or deaths) that could be reduced by lowering the age-, sex-, and race/ethnicity-specific population's systolic BP level to treatment goals based on guideline treatment categories. We then multiplied the age-, sex-, and race/ethnicity-specific PARs by the total number of annual CVD events (or deaths) in the US population aged ≥40 years to estimate the absolute number of annual events (or deaths) that could be reduced. Additionally, we estimated the numbers-needed-to-treat (NNT) by calculating the inverse of the estimated population-level absolute risk reduction. This process was conducted for each age, sex, race, and guideline category and aggregated. Additionally, we conducted a sensitivity analysis to estimate the reductions in numbers of events (or deaths) assuming 25%, 50%, and 75% of individuals reach guideline-specific SBP targets.
Uncertainty Estimation
We accounted for uncertainty in the estimation of the proportion of systolic BP categories, annual event rates, and hazard ratios of BP treatment effects using Monte Carlo simulation. 19 adapted from an approach for PAR confidence interval estimation. 20 For each age-, sex-, and race/ethnicity-specific PAR calculation, numbers were randomly drawn from assumed distributions for the prevalence of systolic BP group i (normal distribution with mean p i and standard error SE pi ) and the HR comparing systolic BP group i to the guideline-specific target (lognormal distribution with mean HR i and SE HRi ). Next, a number was randomly drawn for the incidence rate (IR) of CVD or mortality (normal distribution with mean IR and standard error SE IR ) and multiplied by the respective US population number to estimate the total number of annual CVD events. Finally, the PAR was multiplied by the total number of events to estimate the number of events reduced. For each age-, sex-, race/ethnicity-, and guideline category and study outcome-specific calculation, 10,000 simulations were conducted for the PAR, events reduced, and NNT. The 2.5 th and 97.5 th percentile estimates of the simulated distributions were used to form 95% confidence intervals. P-values for the differences between events reduced and NNT comparing the two guidelines were estimated by calculating z-scores and associated p-values, using a pooled variance approach. Variances of events reduced and NNT were estimated from the confidence intervals resulting from simulation.
Assessing Adverse Events
We systematically searched published clinical trials targeting systolic BP <130 mmHg using MEDLINE and EMBASE. 17 Data on adverse events were extracted from each study independently and in duplicate by at least two investigators. Absolute risk differences between intervention and control groups in adverse events were combined using inverse variance weighting. Risk differences were applied to the number of individuals recommended to lower systolic BP<130 mmHg per the 2017 guideline to estimate the number of adverse events expected. Three trials (Action to Control Cardiovascular Risk in Diabetes trial, Systolic Blood Pressure Intervention Trial, and Secondary Prevention of Small Subcortical Strokes Trial) achieved systolic BP <130 mmHg in the intensive treatment group, and reported adverse events were included in this analysis. [21] [22] [23] [24] Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, North Carolina) and R version 3.4.2 (R Project for Statistical Computing). 
